ArticleClinical and experimental nephrology2009

Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats.

Tadashi Okada et al.PubMed ↗Publisher ↗

No numbers read from the abstract.